Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Maytansinoid DM4, a naturally occuring maytansine analogue, is a highly potent/cytotoxic antitubulin agent with anticancer properties. Maytansinoids have been shown to be able to disrupt microtubule function. Maytansinoid DM4 can be used for the preparation of antibody drug conjugates such as Anetumab ravtansine (BAY 94-9343) and Indatuximab ravtansine (BT062).
ln Vitro |
A novel thiol-containing powerful maytansinoid is DM4, a structural analogue of maytansine. A cytotoxic maytansinoid medication is DM4. It is synthesized to form disulfide bonds between maytansinoids and antibodies. Maytansinoids potently suppress microtubule dynamics, causing a mitotic block and consequent apoptotic cell death. They do this by inhibiting tubulin polymerization and microtubule assembly and by enhancing microtubule destabilization[1].
|
---|---|
References |
[2]. Schönfeld K, Zuber C, Pinkas J, Häder T, Bernöster K, Uherek C. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J Hematol Oncol. 2017 Jan 11;10(1):13. doi: 10.1186/s13045-016-0380-0. PubMed PMID: 28077160; PubMed Central PMCID: PMC5225632.
|
Molecular Formula |
C38H54N3O10SCL
|
---|---|
Molecular Weight |
780.371
|
Exact Mass |
779.32
|
Elemental Analysis |
C, 58.49; H, 6.98; Cl, 4.54; N, 5.38; O, 20.50; S, 4.11
|
CAS # |
796073-69-3
|
Related CAS # |
DM4-d6
|
Appearance |
Solid powder
|
SMILES |
C/C(CC1=CC(OC)=C(Cl)C(N(C(C[C@]([C@]2(C)O[C@H]2[C@@H]3C)([H])OC([C@@H](N(C(CCC(C)(C)S)=O)C)C)=O)=O)C)=C1)=C\C=C\[C@@H](OC)[C@](NC4=O)(C[C@]3([H])O4)O
|
InChi Key |
JFCFGYGEYRIEBE-YVLHJLIDSA-N
|
InChi Code |
InChI=1S/C38H54ClN3O10S/c1-21-12-11-13-28(49-10)38(47)20-27(50-35(46)40-38)22(2)33-37(6,52-33)29(51-34(45)23(3)41(7)30(43)14-15-36(4,5)53)19-31(44)42(8)25-17-24(16-21)18-26(48-9)32(25)39/h11-13,17-18,22-23,27-29,33,47,53H,14-16,19-20H2,1-10H3,(H,40,46)/b13-11+,21-12+/t22-,23+,27+,28-,29+,33+,37+,38+/m1/s1
|
Chemical Name |
(14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-(4-mercapto-4-methylpentanoyl)-N-methyl-L-alaninate
|
Synonyms |
Maytansinoid DM4; DM4, Ravtansine, Soravtansine
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~128.14 mM )
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.20 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+ 40% PEG300+ 5% Tween-80+ 45% saline: ≥ 2.5 mg/mL (3.20 mM) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.2814 mL | 6.4072 mL | 12.8144 mL | |
5 mM | 0.2563 mL | 1.2814 mL | 2.5629 mL | |
10 mM | 0.1281 mL | 0.6407 mL | 1.2814 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03552471 | Active, not recruiting | Other: Laboratory Biomarker Analysis Biological: Mirvetuximab Soravtansine |
BRCA1 Gene Mutation BRCA2 Gene Mutation Folate Receptor Alpha Positive |
Ohio State University Comprehensive Cancer Center | July 12, 2018 | Phase 1 |
NCT03126630 | Active, not recruiting | Biological: Anetumab Ravtansine Other: Laboratory Biomarker Analysis |
Pleural Malignant Mesothelioma | National Cancer Institute (NCI) | October 4, 2018 | Phase 1 Phase 2 |
NCT03045393 | Withdrawn | Drug: Mirvetuximab Soravtansine | Breast Cancer Triple Negative | Duke University | April 17, 2017 | Phase 1 |
NCT03106077 | Completed | Biological: Mirvetuximab Soravtansine |
M.D. Anderson Cancer Center | Duke University | June 5, 2017 | Phase 2 |
Apoptosis induced by DM4 and/or AVE9633 in presence or absence of Zosuquidar in HL60, K562 and their variant P-gp expressing cells. The sensitivity of HL60 and HL60/ADR cells to DM4 and AVE9633 with or without MRP inhibitor. [1].BMC Cancer. 2009 Jun 23;9:199. td> |
The sensitivity of HL60 and HL60/ADR cells to DM4 and AVE9633 with or without MRP inhibitor. [1].BMC Cancer. 2009 Jun 23;9:199. td> |
Apoptosis induced by DM4 and AVE9633 in the presence or absence of MRP inhibitor MK571 in HL60 an HL60/ADR cells. [1].BMC Cancer. 2009 Jun 23;9:199. td> |